"Biota is confident that laninamivir is a product with many patient attributes and with value that can be realised to the benefit of shareholders. We continue to negotiate with prospective licensees and along with our co-owner Daiichi Sankyo, to explore other options capable of delivering value.
We will continue to keep shareholders updated to the extent possible, during sensitive commercialisation negotiations."
Regards Kangaroo1
BTA Price at posting:
91.0¢ Sentiment: Hold Disclosure: Held